Los agonistas del receptor de GLP-1 pueden ser apropiados para personas con diabetes tipo 2, obesidad (IMC 30) o sobrepeso con comorbilidades que no responden adecuadamente a cambios de estilo de vida
We'll look at ongoing research, emerging trends, and how this approach fits into the broader landscape of obesity treatment
Fat loss improved by up to 27% vs semaglutide alone
However, if you have type 2 diabetes, you may qualify for GLP-1 medications approved for diabetes management (Ozempic, Mounjaro) regardless of BMI, and weight loss occurs as a secondary benefit
The duration of Semaglutide GLP-1 treatment for weight loss depends on various factors, including the individuals weight loss goals, response to the medication, and overall health
Social determinants of health Social and financial hardships can negatively impact an individuals mental health, motivation, and capacity to engage in self-management practices, increasing the risk for elevated HbA 1c and complications
